The significance of lumican expression in ovarian cancer drug-resistant cell lines

Andrzej Klejewski; Karolina Sterzyńska; Karolina Wojtowicz; Monika Świerczewska; Małgorzata Partyka; Maciej Brązert; Michał Nowicki; Maciej Zabel; Radosław Januchowski

doi:10.18632/oncotarget.20169

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The significance of lumican expression in ovarian cancer drug-resistant cell lines

Andrzej Klejewski _, Karolina Sterzyńska, Karolina Wojtowicz, Monika Świerczewska, Małgorzata Partyka, Maciej Brązert, Michał Nowicki, Maciej Zabel and Radosław Januchowski

PDF | HTML | How to cite

Oncotarget. 2017; 8:74466-74478. https://doi.org/10.18632/oncotarget.20169

Metrics: PDF 1327 views | HTML 2446 views | ?

Abstract

Andrzej Klejewski1,2, Karolina Sterzyńska3, Karolina Wojtowicz3, Monika Świerczewska3, Małgorzata Partyka3, Maciej Brązert4, Michał Nowicki3, Maciej Zabel3,5 and Radosław Januchowski3

1Department of Nursing, Poznań University of Medical Sciences, Poznań, Poland

2Department of Obstetrics and Womens Diseases, Poznań University of Medical Sciences, Poznań, Poland

3Department of Histology and Embryology, Poznań University of Medical Sciences, Poznań, Poland

4Division of Infertility and Reproductive Endocrinology, Department of Gynecology, Obstetrics and Gynecological Oncology, Poznań University of Medical Sciences, Poznań, Poland

5Department of Histology and Embryology, Wrocław Medical University, Wrocław, Poland

Correspondence to:

Andrzej Klejewski, email: [email protected]

Keywords: drug resistance, ovarian cancer, lumican, collagen

Received: April 28, 2017 Accepted: June 30, 2017 Published: August 10, 2017

ABSTRACT

Purpose: The aim of the present study is to determine the expression of LUM in drug-resistant ovarian cancer cell lines.

Methods: Doxorubicin- (DOX), topotecan- (TOP) and vincristine- (VIN) resistant variants of the W1 ovarian cancer cell line were used in this study. We used quantitative real-time polymerase chain reactions to determine LUM mRNA levels. Protein expression was detected using Western blot and immunocytochemistry assays. Protein glycosylation was investigated using PGNase F digestion. Immunohistochemistry assays were used to determine protein expression in ovarian cancer patients.

Results: We observed increased expression of LUM in drug-resistant cell lines at both the mRNA and the protein level. The most abundant LUM expression was observed in TOP-resistant cell line. We observed LUM bands that corresponded to different molecular masses, and the most abundant LUM form was the secreted form, which had a mass of 50 kDa. Double immunofluorescence analysis showed co-expression of LUM and COL3A1 as well as the presence of extracellular COL3A1 in the TOP-resistant cell line. Finally, we detected the LUM protein in ovarian cancer tissue.

Conclusion: The expression of LUM in cytostatic-resistant cell lines suggests its role in drug resistance. The co-expression of LUM and COL3A1 indicates the significance of LUM in collagen fibre assembly. Expression in ovarian cancer tissue suggests that LUM can play a role in ovarian cancer pathogenesis in ways similar to other cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20169

Publication Alerts

Research Papers:

The significance of lumican expression in ovarian cancer drug-resistant cell lines

Abstract